Inhaled Sedation With Sevoflurane for Acute Respiratory Distress Syndrome (ARDS)
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Inhaled Sedation With Sevoflurane for Acute Respiratory Distress Syndrome (ARDS)
-
Narrated by:
-
By:
About this listen
ARDS, which is characterized by hypoxemic respiratory failure and inflammatory injury to the lungs, has a mortality rate of 30% to 40%. Balasubramanian Venkatesh, MD, of the George Institute for Global Health joins JAMA Deputy Editor Kristin Walter, MD, MS, to discuss the effects of inhaled sedation with sevoflurane for patients with moderate to severe ARDS.
Related Content:
- Sevoflurane Sedation in Acute Respiratory Distress Syndrome
- Inhaled Sedation in Acute Respiratory Distress Syndrome
activate_mytile_page_redirect_t1
What listeners say about Inhaled Sedation With Sevoflurane for Acute Respiratory Distress Syndrome (ARDS)
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.